Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page
Glutamate Cascade Research

The Glutamate Cascade: Common Pathways of Central Nervous System Disease States

Program List

Click on title to go to corresponding abstract.

Sunday, May 3, 1998 - Arrival of Participants
5:00 p.m. - 7:00 p.m.Reception and Posters
Visitors Center Level and Nobel Laureate Level
Building 10
Monday, May 4, 1998
8:00 a.m. - 9:00 a.m.Registration
9:00 a.m. - 9:25 a.m.Introduction for NINDSAudrey Penn, M.D.
Acting Director, NINDS, NIH
Introduction for NIAAAEnoch Gordis, M.D.
Director, NIAAA, NIH
9:25 a.m. - 9:35 a.m."Pooling Medications Development Initiatives on Glutamate and CNS Disorders Across Intramural and Extramural NIH Worlds"Barbara H. Herman, Ph.D.
Chair, Glutamate Cascade Meeting
May 4th Morning Session Presentations

Philip H. Sheridan, M.D., Chair
9:35 a.m. - 10:15 a.m.Glutamate Receptors
"Overview of Glutamate Receptors" and "Kainate Receptor Deficient Mice"
Stephen F. Heinemann, Ph.D.
The Salk Institute
10:15 a.m. - 10:55 a.m."Manipulating Glutamatergic Neurotransmission as a Strategy for Drug Development" and "Glutamate and the Ischemic Brain"Dennis W. Choi, M.D., Ph.D.
Washington University
School of Medicine
10:55 a.m. - 11:15 a.m.Break
11:15 a.m. - 11:45 a.m."Glutamate Neurotransmission in Epilepsy: New Treatment Strategies"Michael A. Rogawski, M.D., Ph.D.
11:45 a.m. - 11:55 a.m.Questions and Answers for Morning PresentationSpeaker Panel
11:55 a.m. - 12:00 p.m.Medications Summary from the MorningPhilip H. Sheridan, M.D.
12:00 p.m. - 1:30 p.m.Lunch
12:00 p.m. - 1:30 p.m.Author-Attended Poster Presentations (GI-A and GI-B)
May 4th Afternoon Session Presentations

Barbara H. Herman, Ph.D., Chair
1:30 p.m. - 2:00 p.m."NMDA Receptors/Nitric Oxide Synthase Cascade in Pain and Opiate Tolerance"Gavril Pasternak, M.D., Ph.D.
Memorial Sloan-Kettering Cancer Center
2:00 p.m. - 2:30 p.m."NMDA Antagonists Modify Opiate Drug-Seeking: Preclinical and Preliminary Clinical Findings"Piotr Popik, M.D., Ph.D.
Polish Academy of Sciences
2:30 p.m. - 3:00 p.m."Glutamate During the Natural History of Psychostimulant Dependence: Synaptic Plasticity and Medications Development"Luigi Pulvirenti, M.D.
University of Rome - Tor Vergata
3:00 p.m. - 3:30 p.m.Break
3:30 p.m. - 4:00 p.m."Glutamate-Mediated Neuroplasticity: Role in Amphetamine Addiction"Marina E. Wolf, Ph.D.
The Chicago Medical School
4:00 p.m. - 4:30 p.m."Alcohol and NMDA Receptor Function"Paula L. Hoffman, Ph.D.
University of Colorado
Health Sciences Center
4:30 p.m. - 5:00 p.m."Acamprosate, A Novel Anti-Craving Compound Acts via Glutamatergic Pathways"Walter Zieglgänsberger, M.D., Ph.D.
Max Planck - Institute of Psychiatry
5:00 p.m. - 5:10 p.m.Questions and Answers for Afternoon PresentationSpeaker Panel
5:10 p.m. - 5:15 p.m.Medications Summary from the AfternoonBarbara H. Herman, Ph.D.
Tuesday, May 5, 1998
May 5th Morning Session Presentations
Neurodegenerative Disorders and Brain Injury

Bradley Wise, Ph.D., Chair
9:00 a.m. - 9:30 a.m."Glutamate Receptor Plasticity in the Hippocampus: Implications for Aging"John H. Morrison, Ph.D.
Mount Sinai School of Medicine
9:30 a.m. - 10:00 a.m."Excitotoxic Apoptoses and Necrosis in AIDS Dementia and Stroke: Potential Treatment with NMDA Open-Channel Blockers and Nitric Oxide-Related Species"Stuart A. Lipton, M.D., Ph.D.
Brigham and Women's Hospital
Harvard Medical School
10:00 a.m. - 10:30 a.m."Glutamatergic Mechanisms in the Cause and Treatment of Parkinson's Disease"J. Timothy Greenamyre, M.D., Ph.D.
Emory University
10:30 a.m. - 11:00 a.m.Break
11:00 a.m. - 11:30 a.m."Glutamatergic Mechanisms in the Pathophysiology and Treatment of Traumatic Brain Injury"Tracy K. McIntosh, Ph.D.
University of Pennsylvania
11:30 a.m. - 12:00 p.m."Role of Glutamate Receptor Maturation in Perinatal Brain Injury"Frances E. Jensen, M.D.
Children's Hospital (Boston)
and Harvard Medical School
12:00 p.m. - 12:10 p.m.Questions and Answers for Morning PresentationSpeaker Panel
12:10 p.m. - 12:15 p.m.Medications Summary from the MorningBradley Wise, Ph.D.
12:15 p.m. - 1:45 p.m.Lunch
12:15 p.m. - 1:45 p.m.Author-Attended Poster Presentations (GII-A and GII-B)
May 5th Afternoon Session Presentations
Psychiatric Disorders/Affective States/Pain

Linda Brady, Ph.D., Chair
1:45 p.m. - 2:15 p.m."Schizophrenia: A Glutamatergic Perspective"Stephen R. Zukin, M.D.
2:15 p.m. - 2:45 p.m."Development of Novel Anxiolytics and Antidepressants via Modulation of Glutamatergic Pathways"Phil Skolnick, Ph.D.
Lilly Research Laboratories
2:45 p.m. - 3:15 p.m.Break
3:15 p.m. - 3:45 p.m."The Role of Glutamate in Chronic Inflammatory Pain and Painful Peripheral Neuropathies"Gary J. Bennett, Ph.D.
Allegheny University of the Health Sciences
3:45 p.m. - 4:15 p.m."Clinical Studies of NMDA and AMPA/Kainate Receptor Blockers in Acute and Chronic Pain"Mitchell B. Max, M.D.
4:15 p.m. - 4:25 p.m.Questions and Answers for Afternoon PresentationSpeaker Panel
4:25 p.m. - 4:30 p.m.Medications Summary from the AfternoonLinda Brady, Ph.D.
4:30 p.m. - 4:45 p.m.Conclusions and New DirectionsBarry J. Hoffer, M.D., Ph.D.
4:45 p.m.Adjournment

[Index][List of Speakers][List of Abstracts][List of Posters]

Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal